Favorable topline data from Regeneron Pharmaceuticals Inc. and partner Sanofi SA’s first of a dozen Phase III trials with alirocumab for high cholesterol gave cause for encouragement, but investors must wait for full details regarding the results, as well as adverse events (AEs). Read More
Too much information, SEC Chairwoman Mary Jo White said as she bemoaned the disclosure overload that’s the byproduct of regulation, social media and a litigious environment. Read More
Sage Therapeutics Inc. added another tiger to its tank, with Arch Venture Partners joining founding investor Third Rock Ventures for a $20 million Series B financing, bringing the company’s total raise to $57.8 million since its launch in 2011. Read More
A team from South San Francisco based Cytomx Therapeutics Inc. reported today that it has developed an EGFR-targeting “probody” that was activated specifically in the tumor microenvironment, allowing its delivery at higher doses than conventional antibodies to both mice and primates. Read More
• Biodefense Therapeutics, of Fort Belvoir, Va. (a joint product management office within the U.S. Department of Defense through a contract with Boston-based Medivector Inc.) reported the successful completion of a Phase II double blind placebo-controlled trial for the anti-influenza drug, T-705a (favipiravir), which clears the way for Phase III trials to begin in November. Read More
• Taris Biomedical Inc., of Lexington, Mass., said it inked a research collaboration with Astrazeneca plc, of London, to evaluate treatments for bladder cancer. Read More
